Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: Involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways

Experimental Hematology

Volumn 31, Issue 3, 2003, Pages 218-225

  Bogner, Christian ^a   Schneller, Folker ^a   Hipp, Susanne ^a   Ringshausen, Ingo ^a   Peschel, Christian ^a   Decker, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; INTERLEUKIN 2; LACTACYSTIN; LIPOCORTIN 5; OLIGONUCLEOTIDE; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEASOME; PROTEIN; PROTEIN BAX; PROTEIN P27; THYMIDINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHROMOSOME; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PATHWAY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DEGRADATION; DRUG INHIBITION; DRUG POTENCY; ENZYME ASSAY; EVALUATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOSTIMULATION; IN VITRO STUDY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

EID: 0037335386     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)01076-7     Document Type: Article

References (52)

1. O'Brien S., Del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 85:2002;306-318.
2. Reed C.J. Apoptosis and cancer. strategies for integrating programmed cell death Semin Hematol. 37:2000;9-16.
3. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. bcl-2 hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 82:1993;1820-1828.
4. McConkey D.J., Chandra J., Wright S.et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and Bax. J Immunol. 156:1996;2624-2630.
5. Meinhardt G., Wendtner C.M., Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia. factors and signaling pathways regulating cell growth and survival J Mol Med. 77:1999;282-293.
6. Kitada S., Andresen J., Akar S.et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia. correlations with in vitro and in vivo chemoresponses Blood. 91:1998;3379-3389.
7. Klein A., Miera O., Bauer O., Golfier S., Schriever F. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia. 14:2000;40-46.
8. Delmer A., Ajchenbaum-Cymbalista F., Tang R.et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 85:1995;2870-2876.
9. Vrhovac R., Delmer A., Tang R., Marie J.P., Zittuon R., Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27 in chronic B-cell lymphocytic leukemia. Blood. 91:1998;4694-4700.
10. Decker T., Schneller F., Hipp S.et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 16:2002;627-634.
11. Almond J.B., Cohen G.M. The proteasome. a novel target for cancer therapy Leukemia. 16:2002;433-443.
12. Yew P.R. Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators. J Cell Physiol. 187:2001;1-10.
13. Voges D., Zwick P., Baumeister W. The 26S proteasome. a molecular machine designed for controlled proteolysis Annu Rev Biochem. 68:1999;1015-1068.
14. Adams J., Palombella V.J., Sausville E.A.et al. Proteasome inhibitors. a novel class of potent and effective antitumor agents Cancer Research. 59:1999;2615-2622.
15. Drexler H.C.A. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A. 94:1997;855-860.
16. Kudo Y., Takata T., Ogawa I.et al. p27kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res. 6:2000;916-923.
17. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., Sherman M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. J Biol Chem. 273:1998;6373-6379.
18. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis. accumulation of wt p53, p21WAF/CIP1, and induction of apoptosis are independent markers of proteasome inhibition Leukemia. 14:2000;1276-1283.
19. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:1998;4342-4348.
20. Hideshima T., Richardson P., Chauhan D.et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2000;3071-3076.
21. Masdehors P., Omura S., Merle-Beral H.et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol. 105:1999;752-757.
22. Chandra J., Niemer I., Gilbreath J.et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 92:1998;4220-4229.
23. Almond J.B., Snowden R.T., Hunter A., Dinsdale D., Cain K., Cohen G.M. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700-kDa Apaf-1 containing apoptosome complex. Leukemia. 15:2001;1388-1397.
24. Drexler H.C., Risau W., Konerding M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14:2000;65-77.
25. Hirsch T., Dallaporta B., Zamzami N.et al. Proteasome activation occurs at an early, premitochondrial step of thymocyte apoptosis. J Immunol. 161:1998;35-40.
26. Cui H., Matsui K., Omura S.et al. Proteasome regulation of activation-induced T-cell death. Proc Natl Acad Sci U S A. 94:1997;7515-7520.
27. Lampert I.A., Wotherspoon A., van Noorden S., Hasserjan R.P. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum Pathol. 30:1999;648-654.
28. Granziero L., Ghia P., Circosta P.et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 97:2001;2777-2783.
29. Liang H., Nishioka Y., Reich C.F., Pisetsky D.S., Lipsky P. Activation of human B cells by phosphorothioate oligonucleotides. J Clin Invest. 98:1996;1119-1129.
30. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 164:2000;944-953.
31. Decker T., Schneller F., Sparwasser T.et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients. Blood. 95:2000;999-1006.
32. Decker T., Schneller F., Kronschnabl M.et al. Immunostimulatory CpG-oligonucleotides induce the expression of functional IL-2 receptors on B-CLL cells. costimulation with IL-2 results in a highly immunogenic phenotype Exp Hematol. 28:2000;558-568.
33. Masdehors P., Merle-Beral H., Maloum K., Omura S., Magdelenat H., Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 96:2000;269-274.
34. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614.
35. Jones D.T., Ganeshaguru K., Virchis A.E.et al. Caspase 8 activation independent of FAS (CD95/Apo-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or γ-radiation. Blood. 98:2001;2800-2807.
36. Genini D., Souichi A., Chao Q.et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 96:2000;3537-3543.
37. Pagano M., Tam S.W., Theodoras A.M.et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
38. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21 (waf1/cip1) gene. Exp Cell Res. 246:1999;280-289.
39. Witko-Sarsat V, Canteloup S, Durant S et al. Cleavage of p21/waf1 by proteinase 3, a myeloid specific serine protease, potentiates cell proliferation. J Bol Chem. 2002;(epub ahead of print).
40. Mimnaugh E.G., Chen H.J., Davies J.R., Celis J.E., Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers. effect on replication, transcription, translation, and the cellular stress response Biochemistry. 36:1997;14418-14429.
41. Arch R.H., Gedrich R.W., Thompson C.B. Tumor necrosis factor receptor associated factors (TRAF). a family of adaptor proteins that regulates life and death Genes Dev. 12:1998;2821-2830.
42. Bosanquet A.G., Sturm I., Wieder T.et al. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B-cell chronic lymphocytic leukemia. Leukemia. 16:2002;1035-1044.
43. Kirsch D.G., Doseff A., Chau B.N.et al. Caspase-3-dependent cleavage of bcl-2 promotes release of cytochrome c. J Biol Chem. 274:1999;21155-21161.
44. Marshansky V., Wang X., Bertrand R.et al. Proteasomes modulate balance among proapoptotic and antiapoptotic bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol. 166:2001;3130-3142.
45. Li B., Dou P. Bax degradation by the ubiquitin/proteasome-dependent pathway. involvement in tumor survival and progression Proc Natl Acad Sci U S A. 97:2000;3850-3855.
46. Zhang X.M., Lin H., Chen C., Chen B.D.M. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces bcl-2 cleavage in human M-07e leukemic cells. Biochem J. 340:1999;127-133.
47. Breitschopf K., Zeiher A.M., Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of Bid. J Biol Chem. 275:2000;21648-21652.
48. Wood D.E., Newcomb E.N. Cleavage of Bax enhances its cell death function. Exp Cell Res. 256:2000;375-382.
49. Thomas A., El Rouby S., Reed J.C.et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia. relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance Oncogene. 12:1996;1055-1062.
50. Susin S.A., Daugas E., Ravagnan L.et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med. 192:2000;571-579.
51. Dumont S., Dürrbach A., Bidere N.et al. Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes. reversibility at low apoptotic insult Blood. 96:2000;1030-1038.
52. Pettitt A.R., Cawley J.C. Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia. Br J Haematol. 109:2000;800-804.